Who are Eryped's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Dificid, Zithromax, Biaxin, CLARITHROMYCIN, Propiocine, Benzamycin.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/erythromycin-ethyl-succinate.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Eryped — Competitive Intelligence Brief

Eryped (Erythromycin ethyl succinate) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Macrolide. Area: Infectious Disease.

marketed Macrolide Infectious Disease Small molecule Live · refreshed every 30 min

Target snapshot

Eryped (Erythromycin ethyl succinate) — Arbor Pharms Llc.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Eryped TARGET	Erythromycin ethyl succinate	Arbor Pharms Llc	marketed	Macrolide		1965-01-01
Dificid	FIDAXOMICIN	Cubist Pharms Llc	marketed	Macrolide Antibacterial [EPC]		2011-01-01
Zithromax	azithromycin	Pfizer Inc.	marketed	Macrolide antibiotic (azalide)	Canalicular multispecific organic anion transporter 1, Taste receptor type 2 member 4, Motilin receptor	1991-11-01
Biaxin	clarithromycin	Generic (originally Abbott/AbbVie)	marketed	Macrolide Antimicrobial [EPC]	Potassium voltage-gated channel subfamily H member 2	1991-10-31
CLARITHROMYCIN	CLARITHROMYCIN		marketed	Macrolide Antimicrobial [EPC]		1991-01-01
Propiocine	ERYTHROMYCIN PROPIONATE		marketed	Macrolide	Bile salt export pump, Bile salt export pump	1967-01-01
Benzamycin	Erythromycin Lactobionate	Pfizer	marketed	Macrolide	Potassium voltage-gated channel subfamily H member 2	1964-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Macrolide class)

· 3 drugs in this class
Arbor Pharms Llc · 1 drug in this class
Pfizer · 1 drug in this class
Pfizer Inc. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Eryped — Competitive Intelligence Brief. https://druglandscape.com/ci/erythromycin-ethyl-succinate. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab